Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials

Award Number: R50CA291823
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/08/2024
PERIOD OF PERFORMANCE END DATE: 07/31/2029

Group Awards By:

View Award Description

Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials - PROJECT SUMMARY Dr. Parikh is a consultant in the Division of Hematology, Department of Medicine at Mayo Clinic in Rochester, MN, and holds the rank of Associate Professor of Medicine with the Mayo Clinic Alix School of Medicine. Dr. Parikh is also a member of the CLL Disease Team and the Lymphoid Malignancies Disease Group of the Mayo Clinic Comprehensive Cancer Center. Since joining on staff at Mayo Clinic, his clinical and research efforts have focused on chronic lymphocytic leukemia (CLL). Dr. Parikh’s overall goal is to improve the care of patients with CLL through the development of novel clinical trials in collaboration with the National Clinical Trials Network (NCTN). To further his objectives, Dr. Parikh proposes with this R50 application to: 1) complete the ECOG-ACRIN trial “EA9161: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)”, and the Alliance for Clinical Trials in Oncology clinical trial “A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)”; and participate in the final outcome analysis, correlative biomarker analysis, and drafting of abstracts and manuscripts; 2) develop the study protocol and serve as the National PI for the next ECOG-ACRIN-led frontline CLL protocol titled “EA9231: Measurable Residual Disease Guided Frontline Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients <70 Years”. In addition to writing the study protocol and activating the study, Dr. Parikh will also be responsible for completing the final analysis, and publish relevant abstracts and manuscripts that will result from this work; and 3) serve as the Mayo Clinic PI for the next Alliance in Clinical Trials in Oncology clinical trial that will test the utility of measurable residual disease in older patients (>65 years) with previously untreated CLL. Additionally, in his role as the Chair of the CLL Disease Team and Vice Chair of the Lymphoid Malignancies Disease Group of the Mayo Clinic Comprehensive Cancer Center, Dr. Parikh oversees the strategic plans for all clinical trials in CLL across the Mayo Enterprise, including NCTN-sponsored trials. Dr. Parikh also participates and actively collaborates on several correlative studies that are being conducted on samples collected from CLL patients enrolled on ECOG-ACRIN trials across the country. Dr. Parikh views the opportunity to submit this application for the NCI Research Specialist (Clinician Scientist) R50 award as a significant and critical opportunity to continue his career goal of developing, implementing, and completing the most cutting-edge and state-of-the-art clinical trials in CLL conducted by the NCTN.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $124,230 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	2	7/24/2025	NON-COMPETING CONTINUATION	$124,230
														Subtotal = $124,230

Issue Date FY: 2024 ( Subtotal = $124,230 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	1	8/8/2024	NEW	$124,230
														Subtotal = $124,230

Grand Total All Awards = $248,460

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials

Award Number: R50CA291823

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/08/2024

PERIOD OF PERFORMANCE END DATE: 07/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer